Patents Assigned to Tranzyme Pharma Inc.
  • Spatially-defined macrocyclic compounds useful for drug discovery
    Publication number: 20050137127
    Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Application
    Filed: August 2, 2004
    Publication date: June 23, 2005
    Applicant: TRANZYME PHARMA INC
    Inventors: Pierre Deslongchamps, Yves Dory, Mark Peterson, Kamel Benakli, Eric Marsault, Luc Ouellet, Mahesh Ramaseshan, Martin Vezina, Daniel Fortin, Ruoxi Lan, Shigui Li, Gerald Villeneuve, Hamid Hoveyda, Sylvie Beaubien
  • Spatially-defined macrocycles incorporating peptide bond surrogates
    Publication number: 20050119169
    Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Application
    Filed: August 2, 2004
    Publication date: June 2, 2005
    Applicant: TRANZYME PHARMA INC.
    Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gerald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark Peterson, Hamid Hoveyda, Sylvie Beaubien, Eric Marsault
  • Macrocyclic antagonists of the motilin receptor
    Publication number: 20050054562
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Application
    Filed: June 18, 2004
    Publication date: March 10, 2005
    Applicant: TRANZYME PHARMA INC.
    Inventors: Graeme Fraser, Eric Marsault, Mark Peterson, Hamid Hoveyda, Sylvie Beaubien, Kamel Benakli